NEW YORK, March 11, 2024 /PRNewswire/ — Pomerantz LLP is investigating claims on behalf of investors of Alignment Healthcare, Inc. (“Alignment” or the “Company”) (NASDAQ: ALHC). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.
The investigation concerns whether Alignment and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
[Click here for information about joining the class action]
On or around March 29, 2021, Alignment conducted its initial public offering (“IPO”), selling 27.2 million shares of common stock priced at $18.00 per share. Then, on February 27, 2024, Alignment issued a press release reporting its fourth quarter and full-year 2023 financial results. Among other items, Alignment reported earnings per share of -$0.25, missing consensus estimates by $0.03.
On this news, Alignment’s stock price fell $1.26 per share, or 18.21%, to close at $5.66 per share on February 28, 2024.
Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered billions of dollars in damages awards on behalf of class members. See www.pomlaw.com.
Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT:Danielle Peyton
Pomerantz LLP
[email protected]
646-581-9980 ext. 7980
SOURCE Pomerantz LLP